tiprankstipranks
Advertisement
Advertisement
Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target
PremiumRatingsImmunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target
2M ago
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
Premium
Ratings
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
2M ago
Immunocore reports Q4 EPS (60c), consensus (20c)
Premium
The Fly
Immunocore reports Q4 EPS (60c), consensus (20c)
2M ago
Immunocore Sets 2026 Strategic Priorities for Melanoma Growth
PremiumCompany AnnouncementsImmunocore Sets 2026 Strategic Priorities for Melanoma Growth
3M ago
Immunocore announces 2026 strategic priorities
Premium
The Fly
Immunocore announces 2026 strategic priorities
3M ago
Immunocore price target raised to $40 from $36 at Morgan Stanley
Premium
The Fly
Immunocore price target raised to $40 from $36 at Morgan Stanley
3M ago
Immunocore price target raised to $37 from $36 at Mizuho
PremiumThe FlyImmunocore price target raised to $37 from $36 at Mizuho
5M ago
Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
Premium
Ratings
Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
5M ago
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD
Premium
The Fly
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100